Cellular and Molecular Biology of Cancer Stem Cells of Hepatocellular Carcinoma
International Journal of Molecular Sciences · 11.01.2023 · 24 (2) · 1417
DOI: 10.3390/ijms24021417 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.01.2023. Verfasst von Kuo-Shyang Jeng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Far Eastern Memorial Hospital, New Taipei City 22060, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Far Eastern Memorial Hospital, Ministry of Science of Technology, Taiwan.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death globally. The cancer stem cells (CSCs) of HCC are responsible for tumor growth, invasion, metastasis, recurrence, chemoresistance, target therapy resistance and radioresistance. The reported main surface markers used to identify liver CSCs include epithelial cell adhesion/activating molecule (EpCAM), cluster differentiation 90 (CD90), CD44 and CD133. The main molecular signaling pathways include the Wnt/β-catenin, transforming growth factors-β (TGF-β), sonic hedgehog (SHH), PI3K/Akt/mTOR and Notch. Patients with EpCAM-positive alpha-fetoprotein (AFP)-positive HCC are usually young but have advanced tumor-node-metastasis (TNM) stages. CD90-positive HCCs are usually poorly differentiated with worse prognosis. Those with CD44-positive HCC cells develop early metastases. Those with CD133 expression have a higher recurrence rate and a shorter overall survival. The Wnt/β-catenin signaling pathway triggers angiogenesis, tumor infiltration and metastasis through the enhancement of angiogenic factors. All CD133+ liver CSCs, CD133+/EpCAM+ liver CSCs and CD44+ liver CSCs contribute to sorafenib resistance. SHH signaling could protect HCC cells against ionizing radiation in an autocrine manner. Reducing the CSC population of HCC is crucial for the improvement of the therapy of advanced HCC. However, targeting CSCs of HCC is still challenging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Far Eastern Memorial Hospital, New Taipei City 22060, Taiwan.
- Department of Hepato Gastroenterology, Linkou Medical Center, Chang-Gung University, Taoyuan City 33305, Taiwan.
- Postgraduate of Institute of Medicine, National Taiwan University, Taipei 10617, Taiwan.
ORCID-Profile: Chiung-Fang Chang
Förderung
- Far Eastern Memorial Hospital
- Ministry of Science of Technology, Taiwan
Zitieren
APA
Jeng, K. S., Chang, C. F., Sheen, I. S., Jeng, C. J., & Wang, C. H. (2023). Cellular and Molecular Biology of Cancer Stem Cells of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 24(2), 1417. https://doi.org/10.3390/ijms24021417
Vancouver
Jeng KS, Chang CF, Sheen IS, Jeng CJ, Wang CH. Cellular and Molecular Biology of Cancer Stem Cells of Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2023;24(2):1417. doi:10.3390/ijms24021417
BibTeX
@article{Jeng2023,
author = {Jeng, Kuo-Shyang and Chang, Chiung-Fang and Sheen, I-Shyang and Jeng, Chi-Juei and Wang, Chih-Hsuan},
title = {Cellular and Molecular Biology of Cancer Stem Cells of Hepatocellular Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {2},
pages = {1417},
doi = {10.3390/ijms24021417}
}
EUVIMED